Cadrenal Therapeutics Inc
CVKD8.810USD
-1.520-14.71%
Close 08/04, 16:00（ET）Quotes delayed by 15 min
8.810USD+8.810After-hours (ET)
16.82MMarket Cap
LossP/E TTM
Cadrenal Therapeutics Inc
8.810
-1.520-14.71%
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
Operating expenses
123.74%3.93M
238.53%4.28M
115.30%2.46M
140.37%2.47M
-58.20%1.76M
17.46%1.26M
17.46%1.14M
112.75%1.03M
2363.18%4.20M
--1.08M
--972.79K
--482.35K
--170.52K
R&D expenses
165.15%1.67M
325.79%1.54M
221.64%784.65K
420.30%1.25M
-80.56%629.02K
210.31%361.13K
332.62%243.95K
19.15%240.96K
18014.88%3.24M
--116.38K
--56.39K
--202.24K
--17.86K
Depreciation, depletion, and amortization
824.12%5.52K
-31.83%407.00
-31.83%407.00
-21.27%470.00
214.21%597.00
-21.45%597.00
17.98%597.00
--597.00
--190.00
--760.00
--506.00
----
----
Operating profit
-123.74%-3.93M
-238.53%-4.28M
-115.30%-2.46M
-140.37%-2.47M
58.20%-1.76M
-17.46%-1.26M
-17.46%-1.14M
-112.75%-1.03M
-2363.18%-4.20M
---1.08M
---972.79K
---482.35K
---170.52K
Net non-operating interest income (expenses)
Non-operating interest expense
----
----
----
--0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
272.65%17.10K
--55.72K
--32.01K
--14.77K
--4.59K
Gains from sale of securities
-10.54%82.60K
-23.89%91.16K
-50.89%52.13K
217.73%73.64K
--92.33K
598955.00%119.77K
3538066.67%106.14K
--23.18K
----
---20.00
--3.00
----
----
Special income (expenses)
----
--0.00
----
--0.00
100.00%0.00
100.00%0.00
100.00%0.00
100.00%0.00
-62073.86%-956.23K
---3.88M
---21.31K
---5.02K
---1.54K
Income before tax
-131.19%-3.85M
-266.00%-4.19M
-132.31%-2.41M
-138.58%-2.39M
67.85%-1.66M
77.16%-1.14M
-1.01%-1.04M
-99.75%-1.00M
-2828.75%-5.17M
---5.01M
---1.03M
---502.14K
---176.65K
Income after tax
-131.19%-3.85M
-266.00%-4.19M
-132.31%-2.41M
-138.58%-2.39M
67.85%-1.66M
77.16%-1.14M
-1.01%-1.04M
-99.75%-1.00M
-2828.75%-5.17M
---5.01M
---1.03M
---502.14K
---176.65K
Net income from continuous operations
-131.19%-3.85M
-266.00%-4.19M
-132.31%-2.41M
-138.58%-2.39M
67.85%-1.66M
77.16%-1.14M
-1.01%-1.04M
-99.75%-1.00M
-2828.75%-5.17M
---5.01M
---1.03M
---502.14K
---176.65K
Net income attributable to controlling interests
-131.19%-3.85M
-266.00%-4.19M
-132.31%-2.41M
-138.58%-2.39M
67.85%-1.66M
77.16%-1.14M
-1.01%-1.04M
-99.75%-1.00M
-2828.75%-5.17M
---5.01M
---1.03M
---502.14K
---176.65K
Net income attributable to common shareholders
-131.19%-3.85M
-266.00%-4.19M
-132.31%-2.41M
-138.58%-2.39M
67.85%-1.66M
77.16%-1.14M
-1.01%-1.04M
-99.75%-1.00M
-2828.75%-5.17M
---5.01M
---1.03M
---502.14K
---176.65K
Basic earnings per share
-33.80%-2.09
-138.77%-2.55
-115.98%-2.18
-74.71%-2.24
78.37%-1.56
88.29%-1.07
47.27%-1.01
-98.24%-1.28
-3063.77%-7.20
---9.13
---1.92
---0.65
---0.23
Diluted earnings per share
-33.80%-2.09
-138.77%-2.55
-115.98%-2.18
-74.71%-2.24
78.37%-1.56
88.29%-1.07
47.27%-1.01
-98.24%-1.28
-3063.77%-7.20
---9.13
---1.92
---0.65
---0.23
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Audit opinions
--
--
--
--
--
--
--
--
--
--
--
--
--
